Trial Profile
Full dose S-1 monotherapy compared to reduced dose S-1/oxaliplatin combination therapy as first-line treatment for older patients with metastatic colorectal cancer S1 eller S1/oxaliplatin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms NORDIC9
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results assessing prognostic value of pre-treatment circulating biomarkers of systemic inflammation presented at the 47th European Society for Medical Oncology Congress
- 03 Jul 2021 Primary endpoint (Progression-free survival) has been met, according to Results presented at the 23rd World Congress on Gastrointestinal Cancer.